Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Operations (2021 - 2025)

Historic Cash from Operations for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$35.0 million.

  • Prime Medicine's Cash from Operations fell 3522.31% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.1 million, marking a year-over-year increase of 4039.43%. This contributed to the annual value of -$122.9 million for FY2024, which is 2572.18% up from last year.
  • Latest data reveals that Prime Medicine reported Cash from Operations of -$35.0 million as of Q3 2025, which was down 3522.31% from -$41.4 million recorded in Q2 2025.
  • Prime Medicine's Cash from Operations' 5-year high stood at $16.2 million during Q4 2024, with a 5-year trough of -$67.7 million in Q1 2024.
  • Its 5-year average for Cash from Operations is -$34.9 million, with a median of -$40.0 million in 2023.
  • In the last 5 years, Prime Medicine's Cash from Operations crashed by 13290.36% in 2022 and then soared by 13703.49% in 2024.
  • Prime Medicine's Cash from Operations (Quarter) stood at -$13.2 million in 2021, then tumbled by 132.9% to -$30.7 million in 2022, then crashed by 42.82% to -$43.9 million in 2023, then soared by 137.03% to $16.2 million in 2024, then crashed by 315.69% to -$35.0 million in 2025.
  • Its Cash from Operations was -$35.0 million in Q3 2025, compared to -$41.4 million in Q2 2025 and -$48.9 million in Q1 2025.